Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 1
Treatment-assignment count: 0
Stratification count: 0
Low Public Signal
KRAS G12D
NSCLC · Small Molecule Inhibitor
KRAS G12D is flagged as low public signal because public trials show inclusion required evidence in 1 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 3
Common snippets: KRAS G12C | KRAS G12C | KRAS G12C
Threshold label: Low
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCTBIO002